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Available online 16 September 2016A ground-breaking high-performance liquid chromatography-diode array detection method based on
microextraction by packed sorbent (MEPS) as sample preparation approach is described herein for determina-
tion of lamotrigine (LTG), a narrow therapeutic index drug, in human plasma and saliva. MEPS variables and
chromatographic conditionswere optimized to achieve appropriate selectivity and sensitivity using small sample
volumes (100 μL). The chromatographic separation of LTG and chloramphenicol [internal standard (IS)] was ac-
complished in b5 min on a C18-column, at 35 °C, using a mobile phase composed by acetonitrile/methanol/
water-triethylamine 0.3% at pH 6.0 (13:13:74, v/v/v) pumped isocratically at 1mL/min. LTG and ISwere detected
at 215 nm. A good linearity was obtained for LTG (r2 ≥ 0.9936) in the range of 0.1–20 μg/mL in plasma and saliva,
with the limit of quantification of 0.1 μg/mL. The method was shown to be precise (RSD ≤14.5%) and accurate
(bias ± 13.4%), and the absolute recovery ranged from 64.9% to 73.6%. The stability of LTG was demonstrated
in plasma and saliva samples in all studied conditions. The proposed assay was applied to the analysis of real
human plasma and saliva samples from epilepsy patients under LTG therapy and the results support its useful-
ness for therapeutic drug monitoring.
© 2016 Elsevier B.V. All rights reserved.Keywords:
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Lamotrigine (LTG) is a broad-spectrum antiepileptic drug (AED)
used as monotherapy or in add-on therapy regimens in adults and chil-
dren [1–4]. LTG is also approved for Lennoux-Gastaut, a rare and intrac-
table form of childhood epilepsy, and for bipolar disorders [5–7].
Structurally, LTG is a 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
(Fig. 1), belonging to the phenyltriazine class, which is chemically unre-
lated to other existing AEDs [2,8]. The physicochemical and pharmaco-
logical properties of LTG determine its unique pharmacokinetic and
pharmacodynamic profile [9].
Therapeutic drug monitoring (TDM) of LTG is of crucial interest in
many clinical circumstances due to the large inter and intraindividual
variability of its systemic drug concentrations, including under steady-niversity of Beira Interior, CICS-
nterior, Av. Infante D. Henrique,state conditions, particularly in cotherapy with other AEDs such as phe-
nytoin, carbamazepine and valproate [10]. Indeed, it is well-established
that plasma/serum LTG concentrations should be monitored during its
concomitant use with other drugs that are enzyme inhibitors (e.g.
valproate, sertraline) or inducers (e.g., phenobarbital, phenytoin, carba-
mazepine, rifampicin, oral contraceptives) [11–14]. Although the thera-
peutic concentration range for LTG has been progressively modified
over the years, the range of 2.5–15 μg/mL has been proposed for seizure
control. However, there is a considerable overlap in serum concentra-
tions among responders and nonresponders, and some refractory pa-
tients may need higher concentration levels [14]. TDM has also an
important clinical value in pregnancy and in children taking LTG, be-
cause plasma drug concentrations are reduced throughout gestation
and the clearance of LTG is higher in children compared to adults and
the elderly [4].
The implementation of TDM for clinical management of LTG therapy
requires the availability of suitable bioanalytical methodologies to sup-
port the LTG concentration measurements in the biological samples of
interest in order to adjust the patient'smedication regimen and achieve
Fig. 1. Chemical structure of lamotrigine (LTG) and chloramphenicol (CAM), used as
internal standard (IS).
222 S. Ventura et al. / Microchemical Journal 130 (2017) 221–228optimal therapeutic outcomes. Therefore, several techniques have been
developed and validated to quantify LTG in different human matrices
(e.g. blood, plasma, serum, urine and saliva) through chromatography
[15–26], immunoassay [23,27] and electrophoresis methods [28–33].
The predominant methodology for LTG bioanalysis is HPLC coupled to
diode array detection (DAD) or UV detection [15,18–20,26,34–49]. On
the other hand, considering all of these LC methods, the sample prepa-
ration/extraction processes employed involved SPME [50], SPE [19,22,
26,45,46,51,52], protein precipitation (PP) [17,28,33–35,40,41,53,54],
LLE [25,43,44,55–61] and microextraction by packed sorbent (MEPS)
[15].
MEPS is indeed a novel sample preparation approach in the field
of bioanalysis, directed towards miniaturization and automation,
and it has been used for qualitative and quantitative bioanalysis of
a vast number of drugs and metabolites [15,62–64]. Specifically, re-
garding the application of MEPS in the bioanalysis of LTG, up to
date and to the best of our knowledge, no method was developed
and validated for human saliva. Saliva was firstly investigated as an
alternative biological fluid for TDM of AEDs in the 1970s [65]. The
use of saliva instead of plasma/serum has several advantages: the
collection of saliva is simple and non-invasive, avoiding discomfort
or stress in patients, particularly in children and the elderly; in addi-
tion, the drug levels in saliva reflect the free non-protein bounded
drug concentrations in blood [65]. Bearing in mind that some recent
reports show a good relationship between salivary concentrations
and plasma/serum concentrations, strengthening the idea that saliva
represents a viable alternative sample to perform TDM [4,8,65–67],
this work was planned to develop and validate a novel HPLC method
for the quantification of LTG in human plasma and saliva using the
innovative MEPS technology in sample preparation.
2. Material and methods
2.1. Materials and reagents
LTG was kindly provided by Bluepharma (Coimbra, Portugal) and
chloramphenicol (CAM), used as internal standard (IS), was pur-
chased from Sigma–Aldrich (St Louis, MO, USA). The chemical struc-
tures of these compounds are shown in Fig. 1. Methanol and
acetonitrile, both of HPLC gradient grade, were purchased from
Chem-Lab (Zedelgem, Belgium) and the ultra-pure water (HPLC
grade, N18 MΩ cm) was prepared by means of a Milli-Q water appa-
ratus fromMillipore (Milford, MA, USA). Triethylamine was acquired
from Merck KGaA (Darmstadt, Germany) and the 85% ortho-
phosphoric acid from Panreac Química SA (Barcelona, Spain). The
MEPS 250 μL syringe and the MEPS BIN (barrel insert and needle)
containing ~4 mg of solid-phase silica–C18 material (SGE Analytical
Science, Australia) were purchased from ILC (Porto, Portugal).
Blank human plasma from healthy blood donors was provided by
the Portuguese Blood Institute after the written consent of each sub-
ject, and saliva was kindly obtained from a set of volunteers.2.2. Stock solutions, calibration standards and QC samples
The LTG stock solution (1 mg/mL) and the working solution
(100 μg/mL) were properly prepared in methanol and then adequately
diluted in water-methanol (50:50, v/v) to afford six spiking solutions
with final concentrations of 0.5, 1, 3.5, 15, 62.5 and 100 μg/mL. Each
one of these solutions were daily used for spiking aliquots of blank
human plasma and saliva in order to prepare six calibration standards
in the concentration range of 0.1–20 μg/mL.
The stock solution of the IS was also prepared in methanol
(1mg/mL) and theworking solution (250 μg/mL)was obtained after di-
luting an appropriate volume of the stock solution in water-methanol
(50:50, v/v). All stock, working and spiking solutions were stored at
4 °C and protected from light, with the exception of the IS working so-
lution which was daily prepared.
QC samples at four concentration levels, representing the lowest
(QCLOQ) and the low (QC1), medium (QC2) and high (QC3) ranges of
the calibration curve, were also independently prepared. For that pur-
pose, aliquots of blank human plasma and saliva were spiked to obtain
final LTG concentrations of 0.1, 0.3, 10 and 18 μg/mL.
2.3. Apparatus and chromatographic conditions
The chromatographic analysis was carried out using an HPLC sys-
tem (Shimadzu LC-2010A HT Liquid Chromatography) coupled with
a DAD (Shimadzu SPD-M20A). All instrumental parts were automat-
ically controlled by the LC solution software (Shimadzu, Kyoto,
Japan). The chromatographic separation of the analytes was carried
out at 35 °C on a reversed-phase LiChroCART® Purospher Star col-
umn (C18, 55 mm × 4 mm; 3 μm particle size) purchased from
Merck KGaA (Darmstadt, Germany). An isocratic elution was applied
at a flow rate of 1.0 mL/min with a mobile phase composed of aceto-
nitrile (13%), methanol (13%) andwater–triethylamine 0.3% (74%) at
pH 6.0, adjusted with 85% ortho-phosphoric acid. The mobile phase
was filtered through a 0.2 μm filter and degassed ultrasonically for
15 min before use. The injection volume was 20 μL and a wavelength
of 215 nm was selected for the detection of all compounds.
2.4. Sample preparation and extraction
The sample preparation procedure was optimized and the final con-
ditions were as follows. It should be noted that saliva was collected
without stimulation and was sonicated prior to sample extraction.
Each aliquot (100 μL) of human plasma or saliva was spiked with
20 μL of the IS working solution, and then 400 μL of ice-cold acetonitrile
was added for protein precipitation in order to minimize sample inter-
ferences in the MEPS step. The mixture was vortex-mixed for 30 s and
centrifuged at 13,500 rpm for 10 min. Afterwards, the resulting super-
natant was evaporated under a gentle nitrogen stream at 45 °C and
the dry residue was reconstituted with 200 μL of 0.3% triethylamine-
water solution (pH 6.0). This reconstituted sample was then submitted
to MEPS.
Previous to MEPS procedures, the sorbent (C18) was activated with
methanol (3 × 200 μL) and passed through ultra-pure water
(3 × 200 μL). Then, the reconstituted sample was drawn through the
needle into the syringe and ejected at a flow rate of approximately
10 μL/s and three draw-eject cycleswere applied on the same sample al-
iquot. After discarding the sample, the sorbent was washed with 200 μL
of ultra-pure water in order to remove matrix interferences and, at the
end, the analytes were eluted with methanol (2 × 30 μL) and diluted
with 90 μL of ultra-purewater. An aliquot (20 μL) of the final sample ex-
tract was injected into the chromatographic system. After the extraction
of each sample, theMEPS device was reconditionedwith 12 × 200 μL of
methanol followed by 5 × 200 μL of ultra-pure water to avoid transfer-
ring the analyte to the next sample (carryover effect). Each MEPS car-
tridge was reused for approximately 200 times before being discarded.
Fig. 2. Typical chromatograms of extracted human plasma and saliva samples obtained by the MEPS/HPLC-DAD method developed: blank plasma (a) and saliva (b); plasma (c) and saliva (d) spiked with the internal standard (IS) and lamotrigine


















LTG 2.803 Acetylsalicylic acid nd Furosemide 3.381
IS 4.174 Ketoprofen 6.530 Escitalopram 18.278
Carbamazepine 12.991 Ibuprofen 23.382 Atenolol 0.839
Phenytoin 12.277 Paracetamol nd Mirtazapine 2.056
Phenobarbital 3.784 Piroxicam 3.778 Amitriptyline nd
Phosphenytoin 3.480 Omeprazole nd Sertraline 1.694
Oxcarbazepine 6.521 Hydrocortisone 12.456 Trazadone 2.111
Primidone 2.013 Theophylline nd Venlafaxine 4.859
Valproic acid 1.986 Glibenclamide 1.700 Mexazolam 1.995
Valerian nd Caffeine 1.116 Nicotine nd
IS, internal standard; nd, not detected in the analytical conditions used.
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The international guidelines on bioanalytical method validation in-
clude several criteria for specific validation parameters that should be
considered in the validation of any quantitative method. Such parame-
ters are selectivity, linearity, LOQ, accuracy, precision, recovery and sta-
bility [68,69].
The selectivity of the method was evaluated by analysing six blank
plasma and saliva samples from different subjects to evaluate the exis-
tence ofmatrix endogenous substances in retention times that could in-
terfere with LTG and the IS. Additionally, the interference of other drugs
that can potentially be co-administered with LTG was evaluated, by
injecting standard drug solutions at 10 μg/mL. The drugs tested in this
selectivity assay included other AEDs (carbamazepine, phenytoin, phe-
nobarbital, phosphenytoin, oxcarbazepine, primidone, valproic acid),
analgesics/antipyretics/anti-inflammatory drugs (acetylsalicylic acid,
ketoprofen, ibuprofen, acetaminophen, piroxicam), antidepressants
(amitriptyline, escitalopram, fluoxetine, mirtazapine, paroxetine, ser-
traline, trazodone, venlafaxine), antihypertensives (atenolol, furose-
mide), anxiolytics/sedatives/hypnotics (clorazepate, mexazolam) and
many other drugs such as sulpiride, hydrocortisone, omeprazole, caf-
feine and nicotine.
The calibration curves for each biological matrix (plasma and sa-
liva) were constructed after preparation of six calibration stan-
dards, including the LOQ, in the concentration range previously
defined, on five distinct days (n = 5), and plotted according to the
LTG/IS peak area ratio against the corresponding nominal concen-
trations. The data were subjected to a weighted linear regression
analysis [70].
The LOQ, defined as the lowest concentration of the calibration
curve that can be measured with adequate intra e interday precision
and accuracy, was evaluated by analysing plasma and saliva
samples prepared in five replicates (n = 5). The LOQ for LTG in
both matrices was assessed considering relative standard deviation
(RSD) values ≤ 20% and deviation from nominal concentration
(bias) within ±20%.
The interday precision and accuracywere evaluated after processing
four QC samples (QCLOQ, QC1, QC2, QC3) prepared in plasma and saliva,
which were tested on five consecutive days (n=5), whereas the intra-
day precision and accuracy were tested by processing five sets of the
corresponding QC samples in a single day (n = 5). The acceptance
criteria for interday and intraday precision is a RSD value lower than
or equal to 15% (or 20% in the LOQ) and for accuracy, a bias value
lower than or equal to 15% (or ±20% in the LOQ).
The absolute recovery of LTG and the IS from human plasma and
saliva samples was determined after the extraction of the corre-
sponding QC samples at three concentration levels (QC1, QC2 and
QC3) in five replicates (n = 5), and by comparing the resultant
peak area with the peak area obtained after the direct injection of
non-extracted LTG and IS solutions at the same nominal concentra-
tions, also in five replicates. The values of absolute recovery for LTG
and the IS were then obtained by the ratio of the peak areas of ex-
tracted and non-extracted samples.
The stability of LTG in human plasma and saliva was investigated for
QC1 and QC3 (n = 5) in different experimental conditions. On the one
hand, in processed samplesmaintained in the autosampler during a pe-
riod of 12 h; and on the other hand, in unprocessed samples, simulating
the short-term and long-term stability conditions, at room temperature
for 4 h, at 4 °C for 24 h, and at−20 °C for 30 days (n=5). Additionally,
the effect of three freeze-thaw cycles on the stability of the LTG in
human plasma and saliva samples was also studied at −20 °C. For
that purpose, aliquots of spiked plasma and saliva samples (QC1 and
QC3) were stored at −20 °C for 24 h, thawed unassisted at room tem-
perature, and when completely thawed, the samples were frozen
again for 24 h under the same conditions until completing the three
freeze-thaw cycles.2.6. Clinical application
Blood and saliva sampleswere obtained from two volunteer patients
after the written consent of each subject. Plasma and saliva aliquots
were analysed to demonstrate the clinical applicability of this
bioanalytical method. Four blood and saliva samples were collect from
each patient, who were under continuous long-term treatment with
LTG, at predefined time-points (2 h, 4 h, 8 h and 12 h) after the first
daily dose of the drug. The period between 0 and 2 h after the oral
drug administration was not considered for sampling because some re-
sidual drug could be retained in themouth (saliva) during this period of
time [71]. Therefore, the collection of blood and saliva samples was only
initiated at 2 h post-dose in order to obtain more reliable values for the
saliva to plasma ratio observed for LTG concentrations.
Blood samples were collected into heparinised tubes, centrifuged at
4000 rpm (4 °C) for 10 min and the plasma was transferred to
eppendorfs and stored at −20 °C until analysis. After mouth flushing,
saliva samples were collected without stimulation into falcon tubes im-
mediately after blood sampling, and stored at −20 °C until analysis. In-
gestion of food, coffee and tobacco was not permitted within the two
hours preceding saliva collection.
3. Results and discussion
A set of preliminary studies were carried out to optimize the
bioanalytical process in order to validate an efficient method for the
quantitative analysis of LTG in both human plasma and saliva. The
final chromatographic and sample preparation/extraction conditions
establishedwere those previouslymentioned in Sections 2.3 and 2.4, re-
spectively. Actually, proper sample preparation is a key step and a pre-
requisite formost bioanalytical procedures. The introduction ofMEPS as
microextraction procedure brought several advantages namely, good
recovery and enough sensitivity, and the use of more reduced sample
and solvent volumes when compared to SPE. Under the defined
bioanalytical conditions the LTG and IS peaks showed a symmetric
shape and were well separated in a running time shorter than 5 min
(Fig. 2). Hence, the analytical instrumentation required, as well as the
simple experimental conditions established, enable the easy implemen-




The chromatograms of blank and spiked human plasma and saliva
samples are presented in Fig. 2. The analysis of blank human plasma
and saliva samples from six healthy volunteers confirmed the absence
of endogenous interferences in the retention times of LTG and the IS.
Most of the tested drugs potentially co-administered with the AED
under investigation (LTG) were also not found to interfere using the
Table 2
Intra and interday precision (% RSD) and accuracy (% bias) values obtained for lamotrigine (LTG) in humanplasma and saliva at the limit of quantification (QCLOQ) concentration and at low




Cexperimental (mean ± SD) (μg/mL) Precision (% RSD) Accuracy (% bias) Cexperimental (mean ± SD) (μg/mL) Precision (% RSD) Accuracy (% bias)
Plasma QCLOQ 0.1 0.109 ± 0.010 14.5 9.3 0.103 ± 0.005 8.8 3.1
QC1 0.3 0.294 ± 0.014 5.6 −2.1 0.278 ± 0.014 5.9 −7.5
QC2 10 9.357 ± 0.372 4.0 −6.4 9.260 ± 0.536 5.8 −7.4
QC3 18 17.208 ± 0.408 2.4 −4.4 16.197 ± 0.713 4.4 −10.0
Saliva QCLOQ 0.1 0.106 ± 0.005 6.3 6.0 0.106 ± 0.013 12.7 5.6
QC1 0.3 0.294 ± 0.011 4.1 −1.9 0.287 ± 0.006 2.2 −4.5
QC2 10 10.333 ± 0.231 2.2 3.3 11.236 ± 0.933 8.3 12.4
QC3 18 18.863 ± 1.369 7.3 4.8 20.420 ± 0.893 4.4 13.4
Cexperimental, experimental concentration; Cnominal, nominal concentration.
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drugs such as furosemide, phenobarbital, fosphenytoin and piroxicam
eluted around the retention time of LTG and/or IS and, therefore, they
can interfere in the quantification of LTG. The retention times observed
for the tested drugs that potentially may be prescribed with the LTG are
indicated in Table 1.
3.1.2. Calibration curves and LOQ
The calibration curves obtained for human plasma and saliva were
linear within the concentration range previously defined and showed
a consistent correlation between the analyte-IS peak area ratios and
the corresponding nominal concentrations. A weighted linear regres-
sion analysis was performed due to the wide calibration range and to
compensate for heteroscedasticity. The calibration curves were subject-
ed to weighted linear regression analysis using 1/χ2 as the weighting
factor. The regression equations of the calibration curves and the corre-
sponding determination coefficients (r2) achieved for LTG in human
plasmawere y= 0.05954 ×−0.00246 (r2 =0.9945) and in human sa-
liva were y = 0.05725 × −0.00127 (r2 = 0.9936). The calibration
curveswere definedwithin the range of 0.1–20 μg/mL in order to largely
cover the therapeutic range of LTG (2.5–15 μg/mL) [14].
The LOQ was experimentally defined as 0.1 μg/mL, in both human
plasma and saliva, with acceptable precision and accuracy (Table 2).
Of note, the LOQ value obtained in plasma using our method is lower
than those achieved bymany other HPLC–UV/DAD techniques reported
in the literature, even though a smaller volume of plasma is employedTable 3
Comparison of determinant bioanalytical aspects between the current method and previ-










Plasma HPLC-DAD 100 μL MEPS 0.10 72% Current
method
HPLC-UV 50 μL SPE 0.20 98% [46]
HPLC-DAD 50 μL SPE 0.25 99% [42]
HPLC-UV 50 μL LLE 0.50 97% [44]
HPLC-UV 1000 μL LLE 0.10 82% [57]
HPLC-UV 500 μL PP 0.50 100% [40]
HPLC-UV 250 μL LLE 1.0 96% [25]
HPLC-UV 500 μL PP 0.10 97–98% [66]
HPLC-UV 200 μL LLE 0.10 95% [8]
HPLC-UV 500 μL LLE 0.02 88% [71]
Saliva HPLC-DAD 100 μL MEPS 0.10 71% Current
method
HPLC-UV 100 μL PP 0.10 106% [8]
HPLC-UV 500 μL PP 0.10 105% [66]
HPLC-UV 500 μL LLE 0.01 ND [71]
DAD, diode array detection; HPLC, high performance liquid chromatography; LLE, liquid-
liquid extraction;MEPS, microextraction by packed sorbent; ND, not determined; PP, pro-
tein precipitation; SPE, solid-phase extraction; UV, ultraviolet.herein [24,37,44,47]. In the case of human saliva, the LOQ obtained
with the current method is similar to those reported in previous
works [8,66,67] (Table 3).
3.1.3. Precision and accuracy
The results for intra and interday precision and accuracy obtained
from QC samples of human plasma and saliva at the four different con-
centration levels (QCLOQ, QC1, QC2 and QC3) are presented in Table 2. In
human plasma, the intra and interday RSD values did not exceed 14.5%,
and the intra and interday bias values varied between −10.0 and 9.3%.
Likewise, in human saliva, the intra and interday RSD values did not ex-
ceed 12.7%, and the intra and interday bias values varied between−4.5
and 13.4%.
3.1.4. Recovery
Overall, the results for LTG absolute recovery from both human plas-
ma and saliva samples, tested at three different concentration levels
(QC1, QC2 and QC3), ranged from 64.9% to 73.6% with RSD values equal
or lower than 7.0%; the detailed data are available in Table 4. The abso-
lute recovery for the IS in human plasma was 65.8% with a RSD value
of 6.8% and in human saliva was 63.9% with a RSD value of 14.7%.
3.1.5. Stability
The results for LTG stability in human plasma and saliva achieved in
the different conditions studied are presented in Table 5. According to
the results obtained, LTG was stable in unprocessed and processed
human plasma and saliva samples in the different handling and storage
conditions.
3.1.6. Clinical application
The plasma and saliva samples from the two volunteer patients were
analysed to demonstrate the clinical usefulness of the method validated
herein. The patient ID1 was receiving LTG 100 mg (p.o.) once-daily,
whereas the other patient (ID2) was taking LTG twice-daily: 150 mg
(p.o.) in the morning and 200 mg (p.o.) at night co-administrated withTable 4
Recovery (values in percentage) of lamotrigine (LTG) from human matrices (plasma and
saliva) at low (QC1),medium (QC2) and high (QC3) concentrations of the calibration range
(n = 5).
Matrix Cnominal (μg/mL) Recovery (%)
Mean ± SD (n = 5) RSD (%)
Plasma QC1 0.3 72.1 ± 5.0 7.0
QC2 10.0 73.6 ± 2.4 3.2
QC3 18.0 70.3 ± 4.8 6.9
Saliva QC1 0.3 70.9 ± 4.0 5.7
QC2 10.0 67.8 ± 4.2 6.2
QC3 18.0 64.9 ± 3.3 5.0
Cnominal, nominal concentration.
Fig. 4. Concentration-time profiles of lamotrigine (LTG) obtained from plasma and saliva
samples collected at 2, 4, 8 and 12 h post-dose (taking as reference the morning dose)
in two patients (ID1 and ID2) under oral LTG therapy (ID1, 100 mg once-daily in the
morning; ID2, 150 mg in the morning, and 200 mg at night in cotherapy with valproic
acid). The corresponding salivary to plasma LTG concentration ratios were also
calculated at 2, 4, 8 and 12 h post-dose and graphically represented for both patients.
Table 5
Stability (values in percentage) of lamotrigine (LTG) at low (QC1) and high (QC3) concen-
trations of the calibration range in unprocessed and processed human plasma and saliva
samples (n = 5).
Stability (values in percentage) of LTG
Analyte Plasma Saliva
QC1 QC3 QC1 QC3
Cnominal (μg/mL) 0.3 18.0 0.3 18.0
Unprocessed samples
Room temperature (4 h) 106.0 94.4 87.6 114.9
4 °C (24 h) 105.6 111.5 85.2 106.3
Freeze-thaw (3 cycles; −20 °C) 89.9 103.2 99.6 98.8
−20 °C (30 days) 113.3 105.1 112.5 103.2
Processed samples
Autosampler (12 h) 95.2 102.7 105.6 97.4
Cnominal, nominal concentration.
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practice for TDMof AEDs [72], this aspectwas adopted in the sample col-
lection protocol for these two patients.
The peaks obtained from the patients' processed samples revealed
symmetry and good resolution, similarly to those obtained in the anal-
ysis of spiked human plasma and saliva samples (Fig. 3). The drug con-
centrations determined in plasma samples were within the therapeutic
range (2.5–15 mg/L) defined for LTG [14,19,65] and, as expected, the
LTG concentrations measured in saliva (free drug concentration) were
lower than those determined in plasma (Fig. 4). Since the total LTG
daily dose received by patient ID1 was less than one third of the total
daily dose taken by patient ID2 (100 mg versus 350 mg), as it could be
anticipated, the LTG concentration levels were substantially lower in
the both samples (plasma and saliva) of patient ID1. Nevertheless, by
normalizing the LTG concentrations obtained by the total daily dose ad-
ministered, a similar proportion was found. In addition, the salivary to
plasma concentration ratio was found to be higher in patient ID2 (0.55
versus 0.37), which was receiving adjunctive therapy (Fig. 4). These re-
sults led us to anticipate the existence of a good relationship between
the LTG concentrations in saliva and plasma in both subjects. Some pre-
vious studies reported saliva/serum LTG ratios of 0.46 in healthy sub-
jects receiving a single oral dose of LTG, and of 0.64 in patients
receiving adjunctive therapy [65,71]. Ryan et al. [67] also studied the re-
lationship between serum and salivary concentrations of LTG in paedi-
atric and adult patients and demonstrated a good saliva/serum
correlation with LTG concentration ratios ranging from 0.40 to 1.19;
Mallayasamy et al. [8] also reported an identical salivary to serum LTG
concentration ratio (0.683). Moreover, observing the LTG
concentration-time profiles (2−12 h) found in plasma and saliva in
both subjects, the high stability of drug concentrations over time andFig. 3. Representative chromatograms of the analysis of real plasma (a) and saliva (b) sample
standard.the high parallelism between salivary and plasma levels should be
highlighted, which clearly supports the use of saliva as a promising
and alternative sample for TDM of patients under LTG treatment.
4. Conclusion
ThisMEPS/HPLC-DADmethod for LTGquantificationwas successful-
ly validated in both plasma and salivamatrices with high sensitivity, se-
lectivity, precision and accuracy. The small sample volume needed for
MEPS processing, the absence of significant chromatographic interfer-
ences from the biological matrices, together with the short running
time in the LTG analysis and the low LOQ achieved, all enhance the clin-
ical interest of this assay. The use of MEPS asmicroextraction procedure
also has several important advantages, which are usually associated
with the miniaturization and automation of bioanalytical procedures.
In spite of the lack of information on a consensual and specific ther-
apeutic range for LTG in saliva, the saliva/plasma correlation achieved in
this study indicates a good relationship between salivary and plasma
drug concentrations, and it is expected that in the near future the use
of saliva samples for TDMof patients under LTG therapywill be a reality
in routine clinical practice.
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AED antiepileptic drug
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MEPS microextraction by packed sorbent
PP protein precipitation
TDM therapeutic drug monitoring
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